TY - JOUR
T1 - Interleukin-1 pathway in active large vessel vasculitis patients with a poor prognosis
T2 - a longitudinal transcriptome analysis
AU - Matsumoto, Kotaro
AU - Suzuki, Katsuya
AU - Yoshimoto, Keiko
AU - Ishigaki, Sho
AU - Yoshida, Hiroto
AU - Magi, Mayu
AU - Matsumoto, Yoshihiro
AU - Kaneko, Yuko
AU - Takeuchi, Tsutomu
N1 - Funding Information:
KM, KS, KY and SI have no conflicts of interest to disclose. HY, MM and YM were employees of Chugai Pharmaceutical Co., Ltd. YK and TT have received research grants from the Chugai Pharmaceutical Co. Ltd.
Funding Information:
We are very grateful to Ms Harumi Kondo, Ms Yumi Ikeda, Ms Yuko Takaishi and Ms Kumiko Tanaka for their technical support. This study was financially supported by grants from the Chugai Pharmaceutical Co. Ltd, Keio University School of Medicine and JSPS KAKENHI (Grant Number JP21K16306).
Publisher Copyright:
© 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc
PY - 2021
Y1 - 2021
N2 - Objectives: Large vessel vasculitis (LVV) is characterised by a high relapse rate. Because accurate assessment of the LVV disease status can be difficult, an accurate prognostic marker for initial risk stratification is required. We conducted a comprehensive longitudinal investigation of next-generation RNA-sequencing data for patients with LVV to explore useful biomarkers associated with clinical characteristics. Methods: Key molecular pathways relevant to LVV pathogenesis were identified by examining the whole blood RNA from patients with LVV and healthy controls (HCs). The data were examined by pathway analysis and weighted gene correlation network analysis (WGCNA) to identify functional gene sets that were differentially expressed between LVV patients and HCs, and associated with clinical features. We then compared the expression of the selected genes during week 0, week 6, remission and relapse. Results: The whole-transcriptome gene expression data for 108 samples obtained from LVV patients (n = 27) and HCs (n = 12) were compared. The pathway analysis and WGCNA revealed that molecular pathway related to interleukin (IL)-1 was significantly upregulated in LVV patients compared with HCs, which correlated with the positron emission tomography vascular activity score, a disease-extent score based on the distribution of affected arteries. Further analysis revealed that the expression levels of genes in the IL-1 signalling pathway remained high after conventional treatment and were associated with disease relapse. Conclusion: Upregulation of the IL-1 signalling pathway was a characteristic of LVV patients and was associated with the extent of disease and a poor prognosis.
AB - Objectives: Large vessel vasculitis (LVV) is characterised by a high relapse rate. Because accurate assessment of the LVV disease status can be difficult, an accurate prognostic marker for initial risk stratification is required. We conducted a comprehensive longitudinal investigation of next-generation RNA-sequencing data for patients with LVV to explore useful biomarkers associated with clinical characteristics. Methods: Key molecular pathways relevant to LVV pathogenesis were identified by examining the whole blood RNA from patients with LVV and healthy controls (HCs). The data were examined by pathway analysis and weighted gene correlation network analysis (WGCNA) to identify functional gene sets that were differentially expressed between LVV patients and HCs, and associated with clinical features. We then compared the expression of the selected genes during week 0, week 6, remission and relapse. Results: The whole-transcriptome gene expression data for 108 samples obtained from LVV patients (n = 27) and HCs (n = 12) were compared. The pathway analysis and WGCNA revealed that molecular pathway related to interleukin (IL)-1 was significantly upregulated in LVV patients compared with HCs, which correlated with the positron emission tomography vascular activity score, a disease-extent score based on the distribution of affected arteries. Further analysis revealed that the expression levels of genes in the IL-1 signalling pathway remained high after conventional treatment and were associated with disease relapse. Conclusion: Upregulation of the IL-1 signalling pathway was a characteristic of LVV patients and was associated with the extent of disease and a poor prognosis.
KW - Takayasu's arteritis
KW - gene expression
KW - giant cell arteritis
KW - interleukin-1
KW - large vessel vasculitis
UR - http://www.scopus.com/inward/record.url?scp=85111242782&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111242782&partnerID=8YFLogxK
U2 - 10.1002/cti2.1307
DO - 10.1002/cti2.1307
M3 - Article
AN - SCOPUS:85111242782
SN - 2050-0068
VL - 10
JO - Clinical and Translational Immunology
JF - Clinical and Translational Immunology
IS - 7
M1 - e1307
ER -